Skip to content

Compare

Zepbound vs Qsymia

Quick read · 5 min

Last reviewed: September 2026Based on 2 clinical trialsEvery claim linked to source

Zepbound (tirzepatide, weekly injection) and Qsymia (phentermine / topiramate ER, daily capsule) are both approved for weight loss in the United States. No head-to-head trial has compared these two drugs. The figures below come from separate trials, each with its own participants, length and comparison group.

At a glance

Zepbound and Qsymia compared on form, trial results, cost and reported side effects
 ZepboundQsymia
FormWeekly injectionDaily capsule
How oftenOnce-weekly injectionDaily oral capsule — no injection
Weight loss in trialsUp to 20.9% — SURMOUNT-1 (72 weeks)Up to 9.8% — CONQUER (56 weeks)
FDA approved20232012
Made byEli LillyVivus
How it worksA single molecule that activates two hunger-regulating signals in the brain — GIP and GLP-1 (both natural hormones released after eating).Phentermine suppresses appetite by triggering the release of adrenaline-like chemicals in the brain's hunger control centre.
Monthly cost, self-pay$299–$1,086/mowith the manufacturer savings programme; list ~$1,086$30–$400/mogeneric; brand runs to $400
Most reported reactionNausea 31% (SURMOUNT-1)Dry mouth 21% (CONQUER)

Every figure in this table is read from the same trial and label records used everywhere else on this site.

Weight loss at the highest dose in each trial

No head-to-head trial has compared these two drugs.

Zepbound(tirzepatide)20.9%

SURMOUNT-1 (72 weeks)

Qsymia(phentermine / topiramate ER)9.8%

CONQUER (56 weeks)

In clinical trials, participants taking tirzepatide lost on average up to 20.9% of their starting body weight, and participants taking phentermine / topiramate ER lost on average up to 9.8%. Those numbers come from two different studies: SURMOUNT-1 enrolled 2,539 adults with obesity or overweight with comorbidities, no type 2 diabetes over 72 weeks against placebo, while CONQUER enrolled 2,487 adults with obesity and at least 2 weight-related health conditions over 56 weeks against placebo. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.

Monthly cost, self-pay

The bar spans the range in each drug's price record — lowest listed price to highest.

Zepbound$299–$1,086/mo

with the manufacturer savings programme; list ~$1,086

Self-pay vials via LillyDirect from $299/month (2.5 mg) to $699/month (10–15 mg), per zepbound.lilly.com on 4 September 2026; list price ~$1,086/month; $25/month copay card for eligible commercial insurance.

Qsymia$30–$400/mo

generic; brand runs to $400

~$30–$80/month generic; ~$200–$400/month brand (Qsymia).

Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Zepbound: $299–$1,086/month. Qsymia: $30–$400/month. Insurance, dose and pharmacy all change both figures.

Side effects reported in the trials

Both trials reported one reaction in common. Each rate is the percentage of participants who reported it in the trial named beside it, so the two columns are not from the same study.

Constipation
Zepbound · SURMOUNT-112%
Qsymia · CONQUER17%

A rate is the share of trial participants who reported that reaction, not a prediction for any one person.

How they differ in practice

How you take it

  • ZepboundOnce-weekly subcutaneous injection (2.5, 5, 7.5, 10, 12.5, 15 mg)
  • QsymiaOnce-daily extended-release capsule

Dose build-up

  • Qsymia3.75/23 mg → 15/92 mg, titrated over 14 weeks

Where a drug is not listed here, its prescribing information sets out its own dose steps.

How soon it acts

  • ZepboundNoticeable appetite reduction typically within 4–8 weeks; significant weight loss by 12–16 weeks
  • QsymiaAppetite suppression typically begins within the first week; significant weight loss by 12–16 weeks

Heart and metabolic findings

  • ZepboundImprovements in systolic/diastolic blood pressure, triglycerides, LDL, and HbA1c across SURMOUNT trials.
  • QsymiaIn CONQUER, significant reductions in blood pressure, waist circumference, triglycerides, and blood glucose were observed.

As stated in each drug’s trial record — not a claim about which drug protects the heart more.

Other findings recorded

  • ZepboundReduced progression to type 2 diabetes; improved sleep apnoea (SURMOUNT-OSA trial)
  • QsymiaGeneric now available (from 2025) — significantly lower cost than GLP-1 drugs; improved blood pressure and triglycerides in CONQUER trial

If you stop taking it

  • ZepboundIn SURMOUNT-4, participants who switched to placebo regained an average of 14.0% body weight over 52 weeks.
  • QsymiaWeight regain after stopping is expected.

Common questions

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Next step most people take

Built with agentic AI tools and not a substitute for medical advice

Last reviewed:

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.